Clinical trial
Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients: Early Action Reduces Long-term Yield in Hidradenitis Suppurativa (EARLY HS 2)
NCT07690319 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients: Early Action Reduces Long-term Yield in Hidradenitis Suppurativa (EARLY HS 2)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- October 15, 2026
- Completion date
- March 15, 2027
- Enrollment
- 186 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.